PepGen shifts focus to PGN-EDODM1 for Myotonic Dystrophy Type 1 after discontinuing PGN-EDO51 for Duchenne Muscular Dystrophy ...
Nutcracker Therapeutics is driving down costs, accelerating speed of processing and improving scalability with an end-to-end, GMP-grade production process. Healthcare is on the cusp of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback